Iron Supplementation for Geriatric Hip Fractures

NCT05489952 | Unknown Phase 4

• 1 other identifier: 20223357010
• Study Type: interventional
• Target: 444
• Locations: 1 country
• Sites: 1

Brief Summary

Geriatric hip fracture is an important disease that affects the health life of the elderly in China. Geriatric hip fracture is often complicated by a variety of comorbidities due to advanced age. And anemia is a common comorbidity. At present perioperative management of geriatric hip fracture, transfusion is only indicated for moderate and severe anemia, while no special medical intervention for mild anemia in China. More and more studies have found that iron can not only correct anemia, but also improve cardiac function, patients' quality of life and function. This study investigated the effect of perioperative iron supplementation on activity tolerance in elderly patients with hip fracture complicated with iron deficiency anemia. The study was a randomized, parallel controlled clinical study. Due to the requirements of the ethics committee, the unblinded setting was cancelled due to ethical considerations. Research will be grouped according to whether to accept iron supplementation treatment, are divided into 2 groups, respectively, iron treatment group and the traditional method. The method of randomization was stratified block randomization. The experimental group added to the intravenous iron sucrose during perioperative period according to the degree of iron deficiency. If there is still a iron deficiency or anemia at discharge, oral ferrous lactate is added after discharge. The outcomes include 6-minute walk distance, Harris score, EQ-5D score six months after surgery, perioperative blood transfusion rate, and so on in the two groups.

Conditions

Hip Fractures; Fragility Fracture; Osteoporotic Fractures

Outcome Measures

Primary Outcomes (1)

• 6-minute walk distance

  The 6-minute walk distance (6 MWD) provides a measure for integrated global response of multiple cardiopulmonary and musculoskeletal systems involved in exercise. The 6 MWT provides information regarding functional capacity, response to therapy and prognosis across a broad range of chronic cardiopulmonary conditions.

  6 months

Secondary Outcomes (2)

• Harris hip score

  6 months

• perioperative blood transfusion rate

  1 week

Study Arms (2)

iron supplement group

EXPERIMENTAL

Drug: iron sucrose and ferrous lactate

control group

NO INTERVENTION

Interventions

iron sucrose and ferrous lactate DRUG

The experimental group added to the intravenous iron sucrose during perioperative period according to the degree of iron deficiency. If there is still a iron deficiency or anemia at discharge, oral ferrous lactate is added after discharge.

Also known as: iron supplementation

iron supplement group

Eligibility Criteria

• Age: 65 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Older Adult (65+)

You may qualify if:

• \>65 years old patients with hip fracture
• Patients with iron deficiency or anemia,
• preoperative hemoglobin \<13g/ dL in males and \<12g/ dL in females, and \>9g/ dL,
• serum ferritin \< 100 ng/ mL or serum ferritin 100-299 ng/ mL or transferrin saturation (TSAT) \<20%

You may not qualify if:

• Coronary artery bypass grafting, percutaneous transluminal coronary angioplasty, and cardiac device implantation (including cardiac resynchronization) within preoperative 30 days
• Acute coronary syndrome, transient ischemic attack or stroke occurred within 30 days before surgery;
• Refused to sign the consent form to be included in the clinical trial group;
• Can't walk before injury;
• Use erythropoietic preparation within 3 months before surgery and oral iron preparation within 4 weeks 30 days before surgery(\> 100 mg/ day)
• Patients with liver and kidney dysfunction

Sponsors & Collaborators

• He Qifei: lead

Study Sites (1)

Shenzhen Second People's Hospita

Shenzhen, Guangdong, 518035, China

RECRUITING

MeSH Terms

Conditions

Hip Fractures; Osteoporotic Fractures

Interventions

Ferric Oxide, Saccharated; ferrous lactate

Condition Hierarchy (Ancestors)

Femoral Fractures; Fractures, Bone; Wounds and Injuries; Hip Injuries; Leg Injuries

Intervention Hierarchy (Ancestors)

Ferric Compounds; Iron Compounds; Inorganic Chemicals; Glucaric Acid; Sugar Acids; Acids, Acyclic; Carboxylic Acids; Organic Chemicals; Hydroxy Acids; Carbohydrates

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: July 31, 2022
• First Posted: August 5, 2022
• Study Start: September 15, 2022
• Primary Completion: February 15, 2025
• Study Completion: August 15, 2025
• Last Updated: September 22, 2022

Record last verified: 2022-09

Locations

CN (1)